← Back to home

REFRACTORY ACUTE MYELOID LEUKEMIA DUE TO LINEAGE SWITCH FROM B ACUTE LYMPHOBLASTIC LEUKEMIA, KMT2A-REARRANGED

Clinical trials for REFRACTORY ACUTE MYELOID LEUKEMIA DUE TO LINEAGE SWITCH FROM B ACUTE LYMPHOBLASTIC LEUKEMIA, KMT2A-REARRANGED explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY ACUTE MYELOID LEUKEMIA DUE TO LINEAGE SWITCH FROM B ACUTE LYMPHOBLASTIC LEUKEMIA, KMT2A-REARRANGED trials appear

Sign up with your email to follow new studies for REFRACTORY ACUTE MYELOID LEUKEMIA DUE TO LINEAGE SWITCH FROM B ACUTE LYMPHOBLASTIC LEUKEMIA, KMT2A-REARRANGED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope for babies with aggressive leukemia: targeted drug trial underway

Disease control Ongoing

This study is testing whether adding a new oral drug called revumenib to standard chemotherapy is safe and effective for infants and young children with a specific, high-risk type of leukemia that has come back or hasn't responded to previous treatments. The trial aims to find th…

Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA DUE TO LINEAGE SWITCH FROM B ACUTE LYMPHOBLASTIC LEUKEMIA, KMT2A-REARRANGED

Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control

Last updated Mar 23, 2026 15:14 UTC

REFRACTORY ACUTE MYELOID LEUKEMIA DUE TO LINEAGE SWITCH FROM B ACUTE LYMPHOBLASTIC LEUKEMIA, KMT2A-REARRANGED

Get alerted when new REFRACTORY ACUTE MYELOID LEUKEMIA DUE TO LINEAGE SWITCH FROM B ACUTE LYMPHOBLASTIC LEUKEMIA, KMT2A-REARRANGED trials appear

New hope for babies with aggressive leukemia: targeted drug trial underway